We are live on ! Find out more
NVS icon

Novartis

878 hedge funds and large institutions have $19.5B invested in Novartis in 2016 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 341 increasing their positions, 311 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more funds holding in top 10

Funds holding in top 10: 2137 (+16)

23% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 56

13% more capital invested

Capital invested by funds: $17.3B → $19.5B (+$2.17B)

10% more repeat investments, than reductions

Existing positions increased: 341 | Existing positions reduced: 311

4% more call options, than puts

Call options by funds: $62.8M | Put options by funds: $60.5M

0% more funds holding

Funds holding: 875878 (+3)

0.1% more ownership

Funds ownership: 9.94%10.04% (+0.1%)

Holders
878
Holders Change
+3
Holders Change %
+0.34%
% of All Funds
23.43%
Holding in Top 10
37
Holding in Top 10 Change
+16
Holding in Top 10 Change %
+76.19%
% of All Funds
0.99%
New
69
Increased
341
Reduced
311
Closed
56
Calls
$62.8M
Puts
$60.5M
Net Calls
+$2.27M
Net Calls Change
+$2.74M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$3.66B -$53.1M -768,260 -2%
Primecap Management
2
Primecap Management
California
$1.72B -$8.28M -119,803 -0.5%
Franklin Resources
3
Franklin Resources
California
$989M -$534K -7,735 -0.1%
BBHC
4
Brown Brothers Harriman & Co
New York
$800M +$2.02M +29,263 +0.3%
Wells Fargo
5
Wells Fargo
California
$618M +$9.22M +133,476 +2%
Fisher Asset Management
6
Fisher Asset Management
Washington
$524M +$5.9M +85,421 +1%
Bank of America
7
Bank of America
North Carolina
$505M +$20M +290,214 +4%
Loomis, Sayles & Company
8
Loomis, Sayles & Company
Massachusetts
$462M +$27.6M +399,821 +7%
UBS Group
9
UBS Group
Switzerland
$448M +$16.8M +243,562 +4%
Manulife (Manufacturers Life Insurance)
10
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$327M +$32.7M +472,724 +12%
Mawer Investment Management
11
Mawer Investment Management
Alberta, Canada
$309M +$27.1M +392,579 +10%
MNA
12
Manning & Napier Advisors
New York
$294M -$5.68M -82,267 -2%
Northern Trust
13
Northern Trust
Illinois
$290M +$113K +1,635 +0%
Parnassus Investments
14
Parnassus Investments
California
$287M +$102M +1,477,276 +61%
State Street
15
State Street
Massachusetts
$261M -$47.5M -687,247 -16%
Macquarie Group
16
Macquarie Group
Australia
$247M +$120M +1,730,426 +108%
Aristotle Capital Management
17
Aristotle Capital Management
California
$226M +$51.1M +739,183 +32%
T
18
Thomaspartners
Massachusetts
$216M +$87.6M +1,268,154 +77%
Lazard Asset Management
19
Lazard Asset Management
New York
$187M +$2.57M +37,201 +1%
Renaissance Technologies
20
Renaissance Technologies
New York
$187M -$77.4M -1,120,353 -31%
Capital Research Global Investors
21
Capital Research Global Investors
California
$186M
CI
22
Cambiar Investors
Colorado
$175M +$17.7M +255,785 +12%
Invesco
23
Invesco
Georgia
$173M -$12.9M -186,070 -7%
ClearBridge Investments
24
ClearBridge Investments
New York
$163M +$9.33M +134,986 +7%
EARNEST Partners
25
EARNEST Partners
Georgia
$154M -$19M -274,541 -12%

NVS Hedge Fund Activity: Q2 2016 in Review

878 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2016, worth a combined $19.5B — up 13% from $17.3B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new NVS positions and 56 closed out — a net gain of 13 holders — while 341 added to existing stakes and 311 trimmed.

The largest buyer was Macquarie Group, adding an estimated $120M. The largest seller was Institutional Capital, exiting entirely with an estimated $276M sold.

  • 878 institutional investors held Novartis (NVS) as of Q2 2016, up from 875 in Q1 2016.
  • Funds reported $19.5B of Novartis stock for Q2 2016, up 13% quarter-over-quarter.
  • 69 funds opened new Novartis positions in Q2 2016 and 56 closed out, a net change of +13 holders.
  • The largest Novartis buyer in Q2 2016 was Macquarie Group, an estimated $120M added.
  • The largest Novartis seller in Q2 2016 was Institutional Capital, an estimated $276M sold.

Based on aggregated 13F filings for Q2 2016.